Designing Products With
Enhanced Tumor Retention
We believe the longer a drug stays in the tumor, the more meaningful the clinical benefit. This is why our anchored-drug conjugates are designed to improve the therapeutic window by binding molecules to aluminum hydroxide.
Anchored Immunotherapy prolongs anti-tumor immune activation, minimizes systemic side effects from drug leakage, and requires fewer dose frequency to achieve benefit.
Anchored Molecules Leading To
Improved Safety Profile
With our Anchored Immunotherapy platform, we are able to optimize drugs whose development has been challenging due to dose-limiting toxicities.
Our First Anchored-Drug Conjugate
ANK-101
After demonstrating potent therapeutic activity with a single dose in multiple preclinical models, our IL-12 anchored-drug conjugate is now being evaluated in patients with advanced solid tumors.
Our Collaborators
Our Investors
